Home >> Products and Services >> Applications
 
Applications
MRI tracking of transplanted cells using Magnelle® contrast agents
 
Magnelle-PoweringTM a cell therapy involves labeling target therapeutic cells with Magnelles to assess the viability, durability, and location of injected cells. Magnelles are intracellular non-pathogenic bacteria genetically programmed to make magnetite particles that create dark (T2) contrast spots, enabling T2/T2* weighted MRI cell tracking in vivo. Magnelles have been validated in a variety of cell types: MSCs, IPSCs, iCMs, primary cells, and other adherent cell types.
 
Additional information and answers to frequently asked questions can be found in this white paper



Advanced Applications
 
Immunotherapy, using genetically engineered T-cells, trained tumor infiltrating lymphocytes, and tumor trained NK cells as examples, is gaining significant traction after strong clinical results. However, some issues remain, particularly with the safety, off-target effects, and durability of these potent therapies. Advanced cell tracking methods can assist in the development of these therapeutics – specifically in assessing off-target localization and durability of the transplanted cells – and thus potentially accelerate clinical success. We are currently refining our labeling procedure to efficiently label certain types of these cells with Magnelles and are actively looking for collaborators and early adopters. If you are interested in working with us on this project, please contact us at BD@bellbiosystems.com.
 
Magnelle agents contain a genome that can be leveraged for a variety of additional functionalities. We, and our partners, are working on several of these next generation products. If you are interested in a collaboration or partnership in the I-O field, please contact us at BD@bellbiosystems.com.  

Publications
  1. Brewer, K., et al., Relaxometry of Bacterially Derived Organelles: A Novel Class of MRI Contrast Agent for Cell Labeling and Tracking. Proc. Intl. Soc. Mag. Reson. Med. 2014. 
  2. Brewer K., et al., Characterization of Magneto-Endosymbionts as MRI Cell Labeling and Tracking Agents. Mol Imaging Biol. 2017 Jun 14. 
  3. Lee KR., et al., Cell Labeling with Magneto-Endosymbionts and the Dissection of the Subcellular Location, Fate, and Host Cell Interactions. Mol Imaging Biol. 2017 Jun 19. 
  4. Mahmoudi M., et al., Novel MRI Contrast Agent from Magnetotactic Bacteria Enables In Vivo Tracking of iPSC-derived Cardiomyocytes. Nature Scientific Reports. 2016 Jun 6.
  5. Santoso MR, Yang PC. Magnetic Nanoparticles for Targeting and Imaging of Stem Cells in Myocardial Infarction. Stem Cells Int. 2016 Apr 3. 

 
 
Products and Services
Magnelle Powering-
Applications
 
 
 
 
 
 
 
Contact Us Sitemap Terms of Use
Follow Bell Biosystems
© 2017 Bell Biosystems. All rights are reserved
Website Security Test